Wei-Wu He
CIK 1542073 · Chairman and CEO · last filed 2022-06-17
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CASI price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
9640 MEDICAL CENTER DRIVE
ROCKVILLE, MD 20850
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CASI Pharmaceuticals, Inc. (CASI) Delisted | Chairman and CEO | 894,553 | $0.28 | $250.5K | $33.62M | 33 | 2022-06-17 |
| CASI Pharmaceuticals, Inc. (ENMD) Delisted | Director | 465,770 | — | — | $0 | 3 | 2013-05-31 |
Recent Filings · Page 2 of 4
36 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-03-30 | CASI Pharmaceuticals, Inc. (CASI) Delisted | Buy (P) | +6,880 | $14.3K | EDGAR |
| 2020-03-27 | CASI Pharmaceuticals, Inc. (CASI) Delisted | Buy (P) | +524,493 | $1.07M | EDGAR |
| 2020-03-19 | CASI Pharmaceuticals, Inc. (CASI) Delisted | Buy (P) | +1,000,002 | $1.53M | EDGAR |
| 2019-12-18 | CASI Pharmaceuticals, Inc. (CASI) Delisted | Exer (X) | +374,321 | $632.6K | EDGAR |
| 2019-08-20 | CASI Pharmaceuticals, Inc. (CASI) Delisted | Buy (P) | +20,000 | $64.0K | EDGAR |
| 2019-08-15 | CASI Pharmaceuticals, Inc. (CASI) Delisted | Buy (P) | +160,000 | $507.2K | EDGAR |
| 2019-06-21 | CASI Pharmaceuticals, Inc. (CASI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-12-21 | CASI Pharmaceuticals, Inc. (CASI) Delisted | Gift (G) | −200,000 | $0 | EDGAR |
| 2018-06-12 | CASI Pharmaceuticals, Inc. (CASI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-03-21 | CASI Pharmaceuticals, Inc. (CASI) Delisted | Mixed | +3,086,419 | $10.00M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.